Advanced Medical Solutions ((GB:AMS)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Advanced Medical Solutions (GB:AMS) is conducting a post-approval study titled Post Approval Study to Evaluate the Safety and Performance of GENTA-FOIL Resorb® for the Prevention of Tissue Adhesions in Hand Surgery. The study aims to assess the safety and effectiveness of Genta-Foil resorb®, a device designed to prevent tissue adhesions following hand surgery, highlighting its significance in improving surgical outcomes.
The intervention being tested is Genta-Foil resorb®, a transparent collagen foil that acts as a temporary barrier during wound healing, preventing tissue adhesions. It contains Gentamicin to protect against bacterial contamination, offering a novel approach to post-surgical care.
This observational study follows a cohort model with a prospective time perspective. It is designed to gather data on the real-world application of Genta-Foil resorb® without random allocation or masking, focusing on its primary purpose of adhesion prevention.
The study began on July 15, 2020, and is currently recruiting participants. The latest update was submitted on February 3, 2025. These dates are crucial as they indicate the study’s progress and ongoing nature, which is essential for stakeholders tracking its development.
The study’s progress could positively influence Advanced Medical Solutions’ stock performance by showcasing innovation and potential market expansion in surgical devices. Investors may view this as a competitive edge, especially in the context of industry advancements in surgical adhesion prevention.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.